ZYXI News and Press, Zynex Inc. From 12/11/22

Summary Two new Breakout Stocks for Week 50 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +131.5% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in VITL +10.4% while PBT...

Zynex Medical to Participate in Piper Sandler 34th Annual Healthcare Conference PR Newswire ENGLEWOOD, Colo. , Nov. 21, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and...

Zynex Named as a Winner in the Deloitte 2022 Technology Fast 500TM Awards for the 4th Consecutive Year PR Newswire ENGLEWOOD, Colo. , Nov. 17, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI ), an innovative medical technology company speciali...

Summary Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +116.9% YTD. This week two picks gained 10% in less than a week with MAG +14.9% and CLNE +15.4% for total portfolio gains over 5%. ...

Zynex ( NASDAQ: ZYXI ) shares gained 3% Tuesday morning after the medical technology company announced an additional $10M share buyback authorization. The program will commence on Nov. 1, 2022 and is scheduled to terminate on Oct. 31, 2023 or when the $10.0 million buy...

At the heart of the medical device space isn’t just new technologies for diagnostics but also substitutes for potentially addictive and life-destroying drugs. Anything you can do with physical-external stimuli instead of pills that impact the brain is possibly a life-changing option fo...

Zynex, Inc. (ZYXI) Q3 2022 Earnings Conference Call October 27, 2022 4:15 AM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, President and Chief Executive Officer Dan Moorhead – Chief Fin...

Zynex press release ( NASDAQ: ZYXI ): Q3 GAAP EPS of $0.13. Revenue of $41.52M (+19.3% Y/Y). Q4 2022 Guidance: The estimated range for fourth quarter 2022 revenue is between $48-$51 million, an increase of approximately 23% from Q4 2021. Adjusted EBITDA for the fou...

Zynex Announces 2022 Third Quarter Earnings PR Newswire ENGLEWOOD, Colo. , Oct. 27, 2022 /PRNewswire/ -- Zynex, Inc . (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

Zynex, Inc. to Announce Third Quarter 2022 Financial Results PR Newswire ENGLEWOOD, Colo. , Oct. 13, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive me...